✦ LIBER ✦

A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients

✍ Scribed by Edward Pan; Susan B. Mitchell; Jerry S. Tsai

Publisher: Springer US
Year: 2008
Tongue: English
Weight: 188 KB
Volume: 88
Category: Article
ISSN: 0167-594X
DOI: 10.1007/s11060-008-9576-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Overall survival of newly diagnosed glio

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

✍ Mary Lou Affronti; Christopher R. Heery; James E. Herndon II; Jeremy N. Rich; Da 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 378 KB

## Abstract ## BACKGROUND: Glioblastoma multiforme (GBM), the most lethal type of brain tumor, has a 1‐year median survival. The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (TMZ) plus RT plus rotational chem

Benefits of interferon-β and temozolomid

Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter : A multicenter study

✍ Kazuya Motomura; Atsushi Natsume; Yugo Kishida; Hiroyuki Higashi; Yutaka Kondo; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 409 KB

## Abstract ## BACKGROUND: The aim of the current study was to catalog genomic and epigenomic abnormalities in newly diagnosed glioblastoma patients and determine the correlation among clinical, genetic, and epigenetic profiles and clinical outcome. ## METHODS: This study retrospectively include

Phase II study of temozolomide and cispl

Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM)

✍ Carmen Balaña; Antonio López-pousa; Alfonso Berrocal; Ricardo Yaya-tur; Ana Herr 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 158 KB

Cost-effectiveness of temozolomide for t

Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme : A report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study

✍ Leida M. Lamers; Roger Stupp; Martin J. van den Bent; Maiwenn J. Al; Thierry Gor 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

## Abstract ## BACKGROUND. The study aimed to compare the cost‐effectiveness of concomitant and adjuvant temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma multiforme versus initial radiotherapy alone from a public health care perspective. ## METHODS. The economic evaluation wa

Palonosetron for the prevention of chemo

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study

✍ Antonio Rozzi; Chiara Nardoni; Michela Corona; Maria Rosa Restuccia; Alessandra 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 114 KB

Commentary on effects of radiotherapy wi

Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466)

✍ Ute Linz 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB